Editas Medicine Inc
EDIT2.560USD
+0.120+4.92%
Market hours （ET）Quotes delayed by 15 min
214.30MMarket Cap
LossP/E TTM
More Details of Editas Medicine Inc Company
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
Company Info
Ticker SymbolEDIT
Company nameEditas Medicine Inc
IPO dateFeb 03, 2016
CEODr. Gilmore O'Neill
Number of employees246
Security typeOrdinary Share
Fiscal year-endFeb 03
Address11 Hurley St
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02141-2110
Phone16174019000
Websitehttps://www.editasmedicine.com/
Ticker SymbolEDIT
IPO dateFeb 03, 2016
CEODr. Gilmore O'Neill
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
67.70K
--
Ms. Amy Parison
Ms. Amy Parison
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
17.51K
-2.48%
Dr. Gilmore O'Neill
Dr. Gilmore O'Neill
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. David T. Scadden, M.D.
Dr. David T. Scadden, M.D.
Independent Director
Independent Director
--
--
Dr. Linda C. Burkly, Ph.D.
Dr. Linda C. Burkly, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
Independent Director
Independent Director
--
--
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
67.70K
--
Ms. Amy Parison
Ms. Amy Parison
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
17.51K
-2.48%
Dr. Gilmore O'Neill
Dr. Gilmore O'Neill
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. David T. Scadden, M.D.
Dr. David T. Scadden, M.D.
Independent Director
Independent Director
--
--
Dr. Linda C. Burkly, Ph.D.
Dr. Linda C. Burkly, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jun 7
Updated: Sat, Jun 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.92%
BlackRock Institutional Trust Company, N.A.
7.26%
Morgan Stanley & Co. LLC
3.05%
Two Sigma Investments, LP
2.94%
Geode Capital Management, L.L.C.
2.32%
Other
75.50%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.92%
BlackRock Institutional Trust Company, N.A.
7.26%
Morgan Stanley & Co. LLC
3.05%
Two Sigma Investments, LP
2.94%
Geode Capital Management, L.L.C.
2.32%
Other
75.50%
Shareholder Types
Shareholders
Proportion
Investment Advisor
30.95%
Investment Advisor/Hedge Fund
12.97%
Research Firm
6.63%
Hedge Fund
5.44%
Bank and Trust
0.80%
Venture Capital
0.57%
Individual Investor
0.33%
Family Office
0.21%
Pension Fund
0.04%
Other
42.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
526
48.45M
57.87%
-23.30M
2025Q1
560
48.21M
57.60%
-23.68M
2024Q4
576
55.95M
67.78%
-11.28M
2024Q3
585
59.63M
72.30%
-8.64M
2024Q2
584
60.69M
73.86%
-19.13M
2024Q1
583
72.72M
88.97%
+367.05K
2023Q4
602
63.06M
77.30%
-13.98M
2023Q3
641
65.84M
80.91%
-11.78M
2023Q2
659
66.65M
82.05%
-208.12K
2023Q1
669
56.55M
82.00%
-9.39M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
7.47M
8.92%
+643.26K
+9.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.08M
7.26%
-551.77K
-8.32%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.55M
3.05%
+1.36M
+113.76%
Mar 31, 2025
Two Sigma Investments, LP
2.46M
2.94%
-841.30K
-25.45%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.94M
2.32%
+135.21K
+7.48%
Mar 31, 2025
State Street Global Advisors (US)
1.85M
2.21%
-26.11K
-1.39%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.61M
1.92%
-551.03K
-25.52%
Mar 31, 2025
UBS Asset Management (Switzerland)
1.60M
1.91%
+430.00K
+36.75%
Mar 31, 2025
BofA Global Research (US)
1.52M
1.81%
+1.08M
+250.36%
Mar 31, 2025
UBS Asset Management Switzerland AG
1.17M
1.4%
+1.17M
--
Jan 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
WisdomTree BioRevolution Fund
1.56%
Invesco NASDAQ Future Gen 200 ETF
0.58%
AXS Green Alpha ETF
0.29%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.01%
View more
WisdomTree BioRevolution Fund
Proportion1.56%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.58%
AXS Green Alpha ETF
Proportion0.29%
iShares Micro-Cap ETF
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
